Forbes recently honored two Maryland biotech CEOs, naming them to the 50 Over 50 list of female visionaries. The local awardees are Helen Sabzevari of Precigen and Carol Nacy of Sequella. Sabzevari focuses on cancer treatment, and Nacy battles tuberculosis.
The beauty of mRNA vaccines is their ability to be quickly updated. Though the vaccine makers are confident in their original vaccines, as COVID-19 continues to change, the vaccines can change, too.
BioNTech to Acquire Kite’s Neoantigen TCR Cell Therapy R&D Platform and Manufacturing Facility in Gaithersburg, MD
BioNTech SE (Nasdaq: BNTX, “BioNTech”) and Kite, a Gilead Company (Nasdaq: GILD, “Kite”) today announced the two companies have entered into a purchase agreement for BioNTech to acquire Kite’s solid tumor neoantigen T cell receptor (TCR) R&D platform and clinical manufacturing facility in Gaithersburg, MD. The acquired Gaithersburg facility will provide production capacity to support clinical trials in the United States and will complement BioNTech’s existing cell therapy manufacturing facility in Idar-Oberstein, Germany. The facility will support the development of BioNTech’s expanding pipeline of novel cell therapies, including cancer product candidates based on its CAR-T Cell amplifying mRNA vaccine (CARVac) and NEOSTIM platforms as well as the newly acquired individualized neoantigen TCR program.